|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
P Gentile, D Byer and LM Pelus
The effects of in vivo administration of prostaglandin E2 (PGE2) on several
hematologic parameters were investigated in intact mice under both
steady-state conditions and in mice hematopoietically rebounding following
a sublethal injection of cyclophosphamide. Intravenous injection of native
PGE2, or 16,16 dimethyl-PGE2, an enzymatically stable analog of PGE2,
resulted in the significant suppression of nucleated bone marrow and
splenic cellularity, total resident nucleated peritoneal cells, and the
absolute number of detectable granulocyte- macrophage progenitor cells
(CFU-GM) per femur or spleen when administered for 3 or 7 consecutive days.
The in vivo effects of 16,16 dimethyl-PGE2 were more pronounced on the
cyclophosphamide-treated mice. Dose titration analysis of the effects of
16,16 dimethyl-PGE2 revealed significant suppression of hematologic
parameters over a concentration range of 10 micrograms-10(-5)
micrograms/mouse/day (10(- 5) M-10(-11) M). The reduction in total
nucleated marrow, splenic, and peritoneal cellularity observed following
PGE2 administration resulted from a selective effect on nonspecific
esterase-positive cells. In situ morphological analysis of the progeny of
CFU-GM proliferating in cultures established from mice treated with PGE2 in
vivo indicated that the reduction in absolute CFU-GM observed resulted from
a preferential effect on those colony-forming cells restricted to
monocyte-macrophage differentiation. Prostaglandin F2 alpha was without
stimulatory or inhibitory effects in vivo on the hematopoietic parameters
investigated.
This article has been cited by other articles:
| |||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 1983 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
